Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Company Limited (Chinese: 江苏恒瑞医药股份有限公司), also known as Jiangsu Hengrui Medicine (Chinese: 恒瑞医药), is a Chinese pharmaceutical company which engaged in the research, development, manufacturing and sales of healthcare products, including antineoplastic (cancer) drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics.[1][2] It is the largest listed pharmaceutical company in China.[3]

Jiangsu Hengrui Medicine Co,.Ltd
Typelisted company
SSE: 600276
IndustryPharmaceuticals
Founded1997
HeadquartersLianyungang, Jiangsu Shanghai, China
Area served
China & global
Key people
Sun Piaoyang (chairman)
Number of employees
24,500 (2020)
Websitewww.hrs.com.cn www.hengruius.com

The company history goes back to 1970. It was originally a state-owned company called Lianyungang Pharmaceutical Factory (Chinese: 连云港制药厂).[4][5] It was established in its current form in 1997 and headquartered in Lianyungang, Jiangsu. It was listed on Shanghai Stock Exchange in 2000.[6] The current headquarters is located in Shanghai and is the seat of the company CEO, several corporate functions and several R&D units. R&D units belonging to the company are located also in Beijing.

In 2020, the company established its clinical R&D organizations the USA (Princeton, New Jersey) and in Europe (Basel, Switzerland).[7][8] The Swiss-based Hengrui Europe Therapeutics AG company also hosts the discovery R&D units, with their focus on protein engineering and on the mRNA technology platform, respectively.

As of December 2020, the company was running ex-China clinical trials esp. in the field of anti-cancer drugs (i.e. anti-PD-1 immune checkpoint inhibitor camrelizumab[9] in hepatocellular carcinoma, a nonsteroidal antiandrogen rezvilutamide in prostate cancer,[10] a PARP inhibitor fluzoparib[11] in solid cancers esp. prostate cancer,[12] a VEGFR2 inhibitor apatinib as a combination therapy in various indications), in metabolic diseases (i.e. type II diabetes[13]), in autoimmune diseases (i.e. interleukin-17 receptor blocker vunakizumab in psoriasis), in HIV treatment and analgesia.

References
  1. Profile of Jiangsu Hengrui Medicine Company Limited
  2. "Search of: Hengrui - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-11-22.
  3. China’s pharmaceutical industry is poised for major growth
  4. "Sun Piaoyang". Forbes. Retrieved 6 February 2021.
  5. "中国最牛"夫妻店"：日赚2亿，一人一家上市公司，掌管2500亿！". finance.sina.cn. 13 December 2020. Archived from the original on 2021-02-06. Retrieved 6 February 2021.
  6. Company Profile
  7. "Hengrui Medicine sets up clinical research and development in Basel". Basel Area Business & Innovation. Retrieved 2020-11-22.
  8. www.zefix.ch https://www.zefix.ch/en/search/entity/list/firm/1448748?name=hengrui&searchType=exact. Retrieved 2020-11-22. Missing or empty |title= (help)
  9. "Search of: camrelizumab - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-12-30.
  10. "Search of: SHR-3680 - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-12-30.
  11. "Search of: SHR-3162 - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-12-30.
  12. "Search of: SHR-3162 - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-12-30.
  13. Jiangsu HengRui Medicine Co., Ltd. (2020-12-09). "Evaluation of the Efficacy and Safety of INS068 Injection and Insulin Degludec Subcutaneous Injection Once Daily in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With One or Two Oral Antidiabetics (A Randomized, Open-Label, Two-Arm, Treat-to-Target, Parallel Controlled Trial)". Cite journal requires |journal= (help)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.